
Mcl-1-Puma inhibitor 8
CAS No. 678158-55-9
Mcl-1-Puma inhibitor 8( Mcl-1-PUMA modulator-8 )
Catalog No. M15591 CAS No. 678158-55-9
Mcl-1-Puma inhibitor 8 is a small-molecule dual-acting compound that targets the apoptotic Mcl-1-PUMA interface with Ki of 0.3 uM (Mcl-1, FPA).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 343 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMcl-1-Puma inhibitor 8
-
NoteResearch use only, not for human use.
-
Brief DescriptionMcl-1-Puma inhibitor 8 is a small-molecule dual-acting compound that targets the apoptotic Mcl-1-PUMA interface with Ki of 0.3 uM (Mcl-1, FPA).
-
DescriptionMcl-1-Puma inhibitor 8 is a small-molecule dual-acting compound that targets the apoptotic Mcl-1-PUMA interface with Ki of 0.3 uM (Mcl-1, FPA), reduces multiple cancer cells and inhibits PUMA-mediated apoptosis; a useful chemical probe to achieve safer cancer therapies by modulating Mcl-1-PUMA interaction.
-
In VitroCLZ-8 (Compound 8) (0-160 μM, 48 h) significantly inhibits PUMA-dependent apoptosis.CLZ-8 (0-1 μM, 2 h) significantly enhance the irradiated cell viability in a dose-dependent manner, provides significant protection for HUVECs, and inhibits overexpressed PUMA.CLZ-8 (0-1 μM, 24 h) attenuates the radiation-induced apoptosis.CLZ-8 (1 μM, 2 h) protects HUVECs from DNA breaks. Apoptosis Analysis Cell Line:DLD-1 cells or HUVEC cellsConcentration:0-160 μM (DLD-1) or 0.01, 0.1 and 1 μM (HUVECs)Incubation Time:48 h (DLD-1) or 24 h (HUVECs)Result:Significantly inhibited PUMA-dependent apoptosis with an IC50 of 38.93 ± 0.91 μM. Attenuated the radiation-induced apoptosis.Western Blot Analysis Cell Line:HUVEC cells Concentration:0.001, 0.01, 0.1 and 1 μM Incubation Time:2 h Result:Suppressed induction of PUMA after radiation, significantly decreased the level of p53. Significantly decreased the level of MCL-1 and increased the level of Bcl-XL.
-
In VivoCLZ-8 (0-400 mg/kg; i.g.; once) shows powerful anti-radiation effects in mice. Animal Model:6-8 week-old male BALB/c mice Dosage:100, 200 and 400 mg/kg Administration:Intragastric administration, once, 30 min prior to irradiation Result:Increased the survival rate of irradiated mice.
-
SynonymsMcl-1-PUMA modulator-8
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number678158-55-9
-
Formula Weight393.505
-
Molecular FormulaC22H23N3O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (127.06 mM)
-
SMILESO=C1N=C(N2CCN(CCO)CC2)S/C1=C\C3=CC=C(C4=CC=CC=C4)C=C3
-
Chemical Name5-([1,1'-biphenyl]-4-ylmethylene)-2-(4-(2-hydroxyethyl)piperazin-1-yl)thiazol-4(5H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Liu J, et al. Oncotarget. 2017 Apr 20;8(33):54236-54242.
molnova catalog



related products
-
MCL-1/BCL-2-IN-2
MCL-1/BCL-2-IN-2 is a potent and selective dual inhibitor of Bcl-2 and Mcl-1.
-
MIK665
MIK665 (S-64315, MIK-665) is a novel potent, selective Mcl-1 inhibitor with potential pro-apoptotic and antineoplastic activities.
-
AT101
AT-101 is the levorotatory isomer of a natural product Gossypol.